Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F16%3AN0000017" target="_blank" >RIV/26475821:_____/16:N0000017 - isvavai.cz</a>

Výsledek na webu

<a href="http://cancerres.aacrjournals.org/content/76/14_Supplement/4943" target="_blank" >http://cancerres.aacrjournals.org/content/76/14_Supplement/4943</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis

Popis výsledku v původním jazyce

Poster AACR 2016 (abstract 4943, vol.76, is.14) describing KRAS Gly12Asp in pancreatic cancer: Although the disease progression of pancreatic ductal adenocarcinoma (PDAC) is very rapid with median survival typically around 3 to 6 months, there are rare cases of patients remaining on therapy for longer periods of time. Early estimation of survival prognosis would allow for rational decisions on complex therapy interventions, including radical surgery and robust systemic therapy regimens. Understandably, there is a great interest in finding prognostic markers that can be used for patient stratification. KRAS, often mutated in PDAC, has been a frequent subject of studies in molecular pancreatic cancer research. It was reported early on that KRAS mutation detected in pancreatic mass itself does not show any prognostic value (1). In this work we have investigated role of various KRAS mutation types on the prognosis of pancreatic cancer patients. Similar to other types of solid tumors it is expected that different KRAS mutations will result in slightly different clinical outcome. The overall survival of PDAC patients correlates with the type of KRAS mutation present in the tumor. The most frequent Gly12Asp (GGT>GAT) mutation confers the worst prognosis resulting in a reduction of survival typically by 3 - 6 months. KRAS testing from EUS-FNAC slides presents a useful tool for stratification of PDAC patients.

Název v anglickém jazyce

Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis

Popis výsledku anglicky

Poster AACR 2016 (abstract 4943, vol.76, is.14) describing KRAS Gly12Asp in pancreatic cancer: Although the disease progression of pancreatic ductal adenocarcinoma (PDAC) is very rapid with median survival typically around 3 to 6 months, there are rare cases of patients remaining on therapy for longer periods of time. Early estimation of survival prognosis would allow for rational decisions on complex therapy interventions, including radical surgery and robust systemic therapy regimens. Understandably, there is a great interest in finding prognostic markers that can be used for patient stratification. KRAS, often mutated in PDAC, has been a frequent subject of studies in molecular pancreatic cancer research. It was reported early on that KRAS mutation detected in pancreatic mass itself does not show any prognostic value (1). In this work we have investigated role of various KRAS mutation types on the prognosis of pancreatic cancer patients. Similar to other types of solid tumors it is expected that different KRAS mutations will result in slightly different clinical outcome. The overall survival of PDAC patients correlates with the type of KRAS mutation present in the tumor. The most frequent Gly12Asp (GGT>GAT) mutation confers the worst prognosis resulting in a reduction of survival typically by 3 - 6 months. KRAS testing from EUS-FNAC slides presents a useful tool for stratification of PDAC patients.

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13638" target="_blank" >NT13638: Klinický význam vyšetření epigenetických faktorů pro zpřesnění diagnostiky, odhadu prognózy a rizika rekurence po kurativní resekci karcinomu pankreatu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů